Dendreon to Host Conference Call on August 3, 2011 to Announce Second Quarter 2011 Financial Results

SEATTLE, July 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, August 3, 2011 at 4:30 p.m. ET to review the second quarter 2011 financial results.  

Access to the discussion may be obtained as follows:



Time:

4:30 PM ET / 1:30 PM PT

Date:

August 3, 2011

Dial-in:

1- 877-548-9590 (domestic) or +1-720-545-0037 (international);


conference pass code: 82447836

Webcast:

www.dendreon.com (homepage and investor relations section)

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-642-1687 or +1-706-645-9291 for international callers; the conference ID number is 82447836. The replay will be available from 7:30 pm ET on August 3 until 11:59 pm ET on August 10.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.



About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

SOURCE Dendreon Corporation

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.